Switch theme
Sign up to access all valuation multiples
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
2014
38
LTM Revenue $2.1M
LTM EBITDA -$10.5M
$11.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Valbiotis has a last 12-month revenue of $2.1M and a last 12-month EBITDA of -$10.5M.
In the most recent fiscal year, Valbiotis achieved revenue of $0.2M and an EBITDA of -$9.9M.
Valbiotis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valbiotis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.1M | $0.2M | XXX | XXX | XXX |
| Gross Profit | $0.8M | $2.9M | XXX | XXX | XXX |
| Gross Margin | 16% | 1525% | XXX | XXX | XXX |
| EBITDA | -$6.9M | -$9.9M | XXX | XXX | XXX |
| EBITDA Margin | -135% | -5241% | XXX | XXX | XXX |
| Net Profit | -$13.2M | -$7.9M | XXX | XXX | XXX |
| Net Margin | -260% | -4210% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Valbiotis's stock price is EUR 1 (or $1).
Valbiotis has current market cap of EUR 16.1M (or $17.3M), and EV of EUR 10.2M (or $11.0M).
See Valbiotis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.0M | $17.3M | XXX | XXX | XXX | XXX | $-0.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Valbiotis has market cap of $17.3M and EV of $11.0M.
Valbiotis's trades at 5.3x LTM EV/Revenue multiple, and -1.0x LTM EBITDA.
Analysts estimate Valbiotis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Valbiotis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $11.0M | XXX | XXX | XXX |
| EV/Revenue | 58.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | XXX | XXX |
| P/E | -1.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpValbiotis's NTM/LTM revenue growth is 140%
Valbiotis's revenue per employee for the last fiscal year averaged $5K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Valbiotis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Valbiotis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Valbiotis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -96% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -5241% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 43% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -5101% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $5K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2650% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4561% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valbiotis acquired XXX companies to date.
Last acquisition by Valbiotis was XXXXXXXX, XXXXX XXXXX XXXXXX . Valbiotis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Valbiotis founded? | Valbiotis was founded in 2014. |
| Where is Valbiotis headquartered? | Valbiotis is headquartered in France. |
| How many employees does Valbiotis have? | As of today, Valbiotis has 38 employees. |
| Is Valbiotis publicy listed? | Yes, Valbiotis is a public company listed on PAR. |
| What is the stock symbol of Valbiotis? | Valbiotis trades under ALVAL ticker. |
| When did Valbiotis go public? | Valbiotis went public in 2017. |
| Who are competitors of Valbiotis? | Similar companies to Valbiotis include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Valbiotis? | Valbiotis's current market cap is $17.3M |
| What is the current revenue of Valbiotis? | Valbiotis's last 12-month revenue is $2.1M. |
| What is the current EBITDA of Valbiotis? | Valbiotis's last 12-month EBITDA is -$10.5M. |
| What is the current EV/Revenue multiple of Valbiotis? | Current revenue multiple of Valbiotis is 5.3x. |
| What is the current EV/EBITDA multiple of Valbiotis? | Current EBITDA multiple of Valbiotis is -1.0x. |
| What is the current revenue growth of Valbiotis? | Valbiotis revenue growth between 2023 and 2024 was -96%. |
| Is Valbiotis profitable? | Yes, Valbiotis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
